August 2024
Biopharma Layoff Tracker 2024: Precigen, Sumitomo, BMS and More Cut Staff
biopharma layoffs, Precigen, Sumitomo, Bristol Myers Squibb, biotech industry, job cuts, restructuring, pharmaceutical companies
Sangamo Secures $50M Upfront in Neurodegenerative Pact with Roche’s Genentech
Sangamo, Roche, Genentech, neurodegenerative, biotech, licensing deal, milestone payments, biobucks
GSK Secures Another Legal Victory in Latest Zantac Verdict
GSK, Zantac, legal victory, cancer claims, ranitidine, NDMA, FDA, pharmaceutical litigation
Sangamo Partners with Genentech for $1.9 Billion Neurology-Focused Deal Using Zinc Finger Technology
Sangamo, Genentech, zinc finger technology, neurology, Alzheimer’s disease, tau gene, biobucks, biopharma, gene therapy, Fabry disease
BioMarin Restricts Roctavian Sales to U.S., Germany, and Italy Amid Stagnant Sales
BioMarin, Roctavian, hemophilia A gene therapy, U.S., Germany, Italy, sales strategy, profitability, cost reduction
Mallinckrodt Sells Immunotherapy Business to CVC Capital for $925 Million
Mallinckrodt, CVC Capital, immunotherapy, Therakos, $925 million deal
Merck & Co., Daiichi Sankyo Strengthen Partnership with New DLL3 Cancer Drug Agreement
Merck & Co., Daiichi Sankyo, DLL3, T-cell engager, MK-6070, small cell lung cancer, neuroendocrine tumors, antibody-drug conjugates, oncology pipeline
Bayer Accelerates Managerial Job Cuts in Ongoing Transformation Efforts
Bayer, managerial job cuts, CEO Bill Anderson, Dynamic Shared Ownership, restructuring, cost savings, pharmaceutical industry